Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JUUL for Smoking Cessation in Head, Neck, and Lung Cancer
NCT05412875Withdrawn
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jan 2024
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Open-label trial of JUUL in Tobacco Use Disorder (TUD) (2 arms), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoints: Feasibility of patients measured by number of screened per month up to 6 months, Acceptance measured by participation rate up to 6 months and 6 more. Planned start Jan 2024; status: withdrawn.
02
Drugs
JUUL
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT05412875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05412875.